sb 203580 has been researched along with mebendazole in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (mebendazole) | Trials (mebendazole) | Recent Studies (post-2010) (mebendazole) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 2,089 | 184 | 438 |
| Protein | Taxonomy | sb 203580 (IC50) | mebendazole (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 5 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 5.5667 | |
| Calmodulin-domain protein kinase 1 | Toxoplasma gondii | 0.67 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukami, T; Mizuno, K; Nakajima, M; Toyoda, Y; Yokoi, T | 1 |
1 other study(ies) available for sb 203580 and mebendazole
| Article | Year |
|---|---|
Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway.
Topics: Anthracenes; Antinematodal Agents; Cell Line, Tumor; Cells, Cultured; Chemokines; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Interleukin-8; Mebendazole; Mitogen-Activated Protein Kinases; Monocytes; Pyridines; Tumor Necrosis Factor-alpha | 2011 |